Mitigating acute chemotherapy-associated adverse events in patients with cancer
NM Kuderer, A Desai, MB Lustberg… - Nature Reviews Clinical …, 2022 - nature.com
Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …
[HTML][HTML] Mitigating acute chemotherapy-associated adverse events in patients with cancer
NM Kuderer, A Desai, MB Lustberg… - Nature Reviews Clinical …, 2022 - sabinai-neji.com
Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …
Mitigating acute chemotherapy-associated adverse events in patients with cancer.
NM Kuderer, A Desai, MB Lustberg… - Nature reviews. Clinical …, 2022 - europepmc.org
Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …
Mitigating acute chemotherapy-associated adverse events in patients with cancer
NM Kuderer, A Desai… - Nature reviews …, 2022 - pubmed.ncbi.nlm.nih.gov
Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …